Engineering - Industrial Equipments · Founded 1991 · www.hleglascoat.com · BSE 522215 · NSE HLEGLAS · ISIN INE461D01028
No Notes Added Yet
Business
HLE Glascoat Ltd. is an Indian engineering company primarily engaged in the manufacturing of specialized industrial equipment. Its core business revolves around producing high-quality Glass Lined Equipment (e.g., reactors, storage tanks, receivers, columns) and various Filtration & Drying Equipment (e.g., Rotary Vacuum Paddle Dryers, Agitated Nutsche Filters). These critical pieces of equipment are essential for a wide range of process industries, including pharmaceuticals, specialty chemicals, agrochemicals, dyes & pigments, and food processing. The company makes money by selling these manufactured equipment units and offering related services, catering to the capital expenditure requirements of these industries.
Revenue Mix
HLE Glascoat Ltd. operates primarily through two main segments:
Glass Lined Equipment: This segment includes glass-lined reactors, storage tanks, receivers, condensers, columns, and accessories. These are vital for processes requiring corrosion resistance and inert surfaces.
Filtration & Drying Equipment: This segment comprises specialized equipment like agitated nutsche filters, rotary vacuum paddle dryers, conical processors, and other allied equipment crucial for separation and drying processes in various industries.
While specific revenue percentages fluctuate, both segments are significant contributors, with Glass Lined Equipment historically forming a substantial part of its business.
Industry
The company operates in the highly specialized industrial equipment manufacturing sector, serving niche but critical requirements of process industries. This industry is characterized by the need for precision engineering, high-quality materials, and strict adherence to industry standards. HLE Glascoat is positioned as one of the leading manufacturers in India for Glass Lined Equipment, competing with both domestic players (such as GMM Pfaudler) and a few international suppliers. Its strong technological capabilities and established presence give it a prominent standing, particularly within the Indian chemical and pharmaceutical sectors.
MOAT
HLE Glascoat possesses several durable advantages:
Specialized Expertise & Technology: Manufacturing glass-lined and high-end filtration/drying equipment requires significant technical know-how, precise engineering, and specialized manufacturing processes that are difficult to replicate quickly.
High Switching Costs: For process industries, integrating new equipment involves significant costs beyond the purchase price, including re-validation, potential process adjustments, and downtime, leading to high switching costs for customers once a supplier is chosen and equipment is installed.
Brand Reputation & Trust: In critical process equipment where reliability, safety, and longevity are paramount, a long-standing reputation for quality and performance builds strong customer trust, acting as a significant barrier for new entrants.
Client Relationships: Deep-rooted relationships with major players in the pharmaceutical and chemical industries built over years of reliable service and product delivery.
Growth Drivers
Capital Expenditure Cycle in Process Industries: Sustained growth and expansion in India's pharmaceutical, specialty chemical, and agrochemical sectors drive demand for new and replacement equipment.
"China Plus One" Strategy: Global diversification of supply chains away from China is boosting manufacturing investments in India, particularly in chemicals and pharmaceuticals, increasing demand for industrial equipment.
API Manufacturing Push: Government initiatives and industry focus on increasing domestic Active Pharmaceutical Ingredient (API) production.
Technological Upgrades: Existing plants require modernization and upgrades, creating a steady demand for advanced and efficient equipment.
Export Opportunities: Potential for expanding market reach into international markets, leveraging its expertise and competitive pricing.
Risks
Cyclicality of Client Industries: Demand for equipment is inherently tied to the capital expenditure cycles of the chemical, pharmaceutical, and agrochemical industries, making it susceptible to economic downturns in these sectors.
Intense Competition: Competition from domestic peers and potential imports can lead to pricing pressures and impact profit margins.
Raw Material Price Volatility: Fluctuations in the prices of key raw materials like steel, glass, and other specialized components can directly impact manufacturing costs and profitability.
Technological Obsolescence: The need for continuous R&D and innovation to keep pace with evolving industry standards and customer requirements.
Regulatory Changes: Stricter environmental, health, and safety regulations in client industries could necessitate costly product or process modifications.
Management & Ownership
HLE Glascoat Ltd. is a promoter-led company, with the promoter group holding a significant stake. The management team typically comprises experienced professionals with deep industry knowledge, having grown the business in a specialized and technically demanding sector. The ownership structure reflects a typical Indian corporate structure with a dominant promoter holding, alongside institutional and public shareholding.
Outlook
HLE Glascoat operates in a crucial segment supporting India's growing industrial manufacturing capabilities. The company is well-positioned to benefit from strong tailwinds in the pharmaceutical, specialty chemical, and agrochemical sectors, driven by domestic growth, API manufacturing push, and the "China Plus One" strategy. Its established brand, technological expertise, and long-standing client relationships provide a solid foundation for growth. However, the business remains exposed to the inherent cyclicality of its end-user industries and intense competition, which could impact order inflows and pricing power. Efficient project execution, continued innovation, and effective management of raw material costs will be critical for sustaining its growth trajectory and profitability in the competitive landscape.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 307 | 227 | 236 | 231 | 334 | 284 | 351 | 327 | 392 | 301 |
| Other Income | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 3 | 1 | 2 |
| Total Income | 309 | 229 | 237 | 233 | 336 | 286 | 353 | 330 | 393 | 302 |
| Total Expenditure | 270 | 205 | 202 | 205 | 282 | 246 | 313 | 305 | 349 | 280 |
| Operating Profit | 38 | 24 | 35 | 28 | 54 | 40 | 40 | 25 | 44 | 23 |
| Interest | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 8 |
| Depreciation | 7 | 7 | 7 | 7 | 8 | 8 | 9 | 10 | 10 | 10 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -3 | -0 | 0 |
| Profit Before Tax | 21 | 7 | 20 | 11 | 37 | 23 | 19 | 4 | 25 | 4 |
| Provision for Tax | 6 | 2 | 5 | 1 | 6 | 5 | 5 | -1 | 5 | 2 |
| Profit After Tax | 15 | 5 | 14 | 10 | 32 | 18 | 14 | 5 | 20 | 2 |
| Adjustments | -5 | -2 | -1 | -2 | -4 | -1 | -2 | -2 | -2 | 1 |
| Profit After Adjustments | 10 | 3 | 14 | 8 | 27 | 16 | 12 | 3 | 18 | 3 |
| Adjusted Earnings Per Share | 1.5 | 0.5 | 2 | 1.2 | 3.9 | 2.4 | 1.7 | 0.4 | 2.6 | 0.4 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 359 | 426 | 442 | 644 | 923 | 960 | 1028 | 1353 | 1371 |
| Other Income | 3 | 5 | 3 | 7 | 8 | 9 | 8 | 9 | 8 |
| Total Income | 362 | 431 | 445 | 652 | 931 | 969 | 1036 | 1362 | 1378 |
| Total Expenditure | 313 | 354 | 354 | 531 | 783 | 842 | 892 | 1211 | 1247 |
| Operating Profit | 49 | 77 | 92 | 120 | 147 | 126 | 144 | 151 | 132 |
| Interest | 15 | 13 | 11 | 14 | 25 | 33 | 39 | 37 | 34 |
| Depreciation | 7 | 7 | 7 | 10 | 22 | 26 | 30 | 36 | 39 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -9 | 0 | -5 | 0 | -7 | -6 |
| Profit Before Tax | 28 | 57 | 74 | 87 | 100 | 62 | 75 | 71 | 52 |
| Provision for Tax | 9 | 17 | 23 | 26 | 30 | 18 | 13 | 14 | 11 |
| Profit After Tax | 19 | 39 | 51 | 61 | 71 | 45 | 62 | 57 | 41 |
| Adjustments | -1 | -1 | 1 | -3 | -1 | -15 | -7 | -7 | -5 |
| Profit After Adjustments | 18 | 38 | 52 | 58 | 70 | 30 | 55 | 49 | 36 |
| Adjusted Earnings Per Share | 5.5 | 5.9 | 8 | 8.5 | 10.2 | 4.3 | 8 | 7.1 | 5.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 32% | 14% | 25% | 0% |
| Operating Profit CAGR | 5% | 1% | 10% | 0% |
| PAT CAGR | -8% | -7% | 2% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -24% | -10% | -22% | 34% |
| ROE Average | 11% | 12% | 19% | 36% |
| ROCE Average | 13% | 14% | 19% | 26% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 41 | 76 | 135 | 254 | 327 | 417 | 478 | 534 |
| Minority's Interest | 1 | 1 | 0 | 0 | 0 | 80 | 76 | 84 |
| Borrowings | 60 | 54 | 55 | 130 | 98 | 147 | 108 | 101 |
| Other Non-Current Liabilities | 4 | 4 | 5 | 43 | 63 | 71 | 56 | 45 |
| Total Current Liabilities | 188 | 200 | 182 | 333 | 407 | 487 | 570 | 604 |
| Total Liabilities | 294 | 335 | 377 | 759 | 894 | 1202 | 1288 | 1368 |
| Fixed Assets | 85 | 94 | 119 | 244 | 317 | 540 | 589 | 625 |
| Other Non-Current Assets | 5 | 12 | 11 | 37 | 18 | 42 | 50 | 26 |
| Total Current Assets | 203 | 229 | 247 | 479 | 559 | 620 | 649 | 716 |
| Total Assets | 294 | 335 | 377 | 759 | 894 | 1202 | 1288 | 1368 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 6 | 1 | 10 | 25 | 3 | 33 | 40 |
| Cash Flow from Operating Activities | 49 | 45 | 48 | 1 | 5 | 95 | 134 | 161 |
| Cash Flow from Investing Activities | -15 | -19 | -29 | -173 | -40 | -45 | -68 | -86 |
| Cash Flow from Financing Activities | -29 | -30 | -10 | 160 | 13 | -19 | -60 | -85 |
| Net Cash Inflow / Outflow | 5 | -5 | 9 | -12 | -22 | 31 | 6 | -10 |
| Closing Cash & Cash Equivalent | 6 | 1 | 10 | 25 | 3 | 33 | 40 | 34 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 5.5 | 5.91 | 8 | 8.52 | 10.23 | 4.35 | 8.04 | 7.12 |
| CEPS(Rs) | 7.71 | 7.21 | 8.89 | 10.39 | 13.61 | 10.3 | 13.39 | 13.39 |
| DPS(Rs) | 0 | 0.9 | 0.8 | 1 | 1.1 | 1.1 | 1.1 | 1.1 |
| Book NAV/Share(Rs) | 9.31 | 11.47 | 17.31 | 36.97 | 47.75 | 61 | 69.99 | 76.87 |
| Core EBITDA Margin(%) | 12.86 | 16.99 | 19.95 | 17.49 | 15.14 | 12.23 | 13.19 | 10.51 |
| EBIT Margin(%) | 11.84 | 16.38 | 19.15 | 15.64 | 13.56 | 9.91 | 11.1 | 7.98 |
| Pre Tax Margin(%) | 7.65 | 13.25 | 16.75 | 13.47 | 10.86 | 6.48 | 7.3 | 5.24 |
| PAT Margin (%) | 5.15 | 9.18 | 11.56 | 9.42 | 7.67 | 4.63 | 6.01 | 4.18 |
| Cash Profit Margin (%) | 6.97 | 10.93 | 13.14 | 11.01 | 10.06 | 7.32 | 8.89 | 6.87 |
| ROA(%) | 6.31 | 12.46 | 14.36 | 10.68 | 8.56 | 4.25 | 4.96 | 4.26 |
| ROE(%) | 61.23 | 75.1 | 54.6 | 33.19 | 24.49 | 11.99 | 13.81 | 11.18 |
| ROCE(%) | 27.32 | 42.13 | 41.93 | 29.26 | 24.22 | 14.07 | 14.22 | 12.9 |
| Receivable days | 33.97 | 33.17 | 46.76 | 61.52 | 77.22 | 91.16 | 74.92 | 61.31 |
| Inventory Days | 133.36 | 121.78 | 124.26 | 117.76 | 106.01 | 110.28 | 120.99 | 97.78 |
| Payable days | 98.32 | 98.33 | 94.24 | 88.14 | 88.33 | 91.88 | 84.55 | 69.91 |
| PER(x) | 6.43 | 16.19 | 56.79 | 127.72 | 49.21 | 93.88 | 31.07 | 35.23 |
| Price/Book(x) | 3.8 | 8.35 | 26.25 | 29.43 | 10.54 | 6.69 | 3.57 | 3.26 |
| Dividend Yield(%) | 0 | 0.94 | 0.18 | 0.09 | 0.22 | 0.27 | 0.44 | 0.44 |
| EV/Net Sales(x) | 0.59 | 1.67 | 6.89 | 11.8 | 3.97 | 3.23 | 1.95 | 1.48 |
| EV/Core EBITDA(x) | 4.31 | 9.19 | 33.23 | 63.26 | 24.89 | 24.58 | 13.91 | 13.21 |
| Net Sales Growth(%) | 0 | 18.66 | 3.65 | 45.74 | 43.34 | 3.97 | 7.05 | 31.67 |
| EBIT Growth(%) | 0 | 64.24 | 21.15 | 18.97 | 24.33 | -24 | 19.89 | -5.38 |
| PAT Growth(%) | 0 | 111.6 | 30.46 | 18.64 | 16.71 | -37.15 | 38.78 | -8.42 |
| EPS Growth(%) | 0 | 7.45 | 35.32 | 6.47 | 20.02 | -57.48 | 84.77 | -11.44 |
| Debt/Equity(x) | 3.79 | 1.32 | 0.81 | 0.82 | 0.76 | 0.87 | 0.73 | 0.59 |
| Current Ratio(x) | 1.08 | 1.14 | 1.36 | 1.44 | 1.37 | 1.27 | 1.14 | 1.19 |
| Quick Ratio(x) | 0.38 | 0.38 | 0.55 | 0.64 | 0.71 | 0.63 | 0.49 | 0.6 |
| Interest Cover(x) | 2.83 | 5.24 | 7.98 | 7.2 | 5.03 | 2.89 | 2.92 | 2.92 |
| Total Debt/Mcap(x) | 1 | 0.16 | 0.03 | 0.03 | 0.07 | 0.13 | 0.2 | 0.18 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.69 | 66.69 | 66.69 | 66.69 | 66.69 | 66.78 | 65.64 | 65.64 | 65.64 | 65.64 |
| FII | 4.28 | 4.27 | 4.07 | 4.01 | 4.12 | 4.01 | 3.7 | 2.14 | 2.27 | 2.05 |
| DII | 3.77 | 3.57 | 3.52 | 3.52 | 3.52 | 4.01 | 4.04 | 4.48 | 4.87 | 4.71 |
| Public | 25.26 | 25.47 | 25.72 | 25.78 | 25.67 | 25.2 | 26.62 | 27.74 | 27.22 | 27.6 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.55 | 4.55 | 4.55 | 4.55 | 4.55 | 4.56 | 4.56 | 4.56 | 4.56 | 4.56 |
| FII | 0.29 | 0.29 | 0.28 | 0.27 | 0.28 | 0.27 | 0.26 | 0.15 | 0.16 | 0.14 |
| DII | 0.26 | 0.24 | 0.24 | 0.24 | 0.24 | 0.27 | 0.28 | 0.31 | 0.34 | 0.33 |
| Public | 1.72 | 1.74 | 1.76 | 1.76 | 1.75 | 1.72 | 1.85 | 1.93 | 1.89 | 1.92 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.95 | 6.95 | 6.95 | 6.95 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +32% | +14% | +25% | — |
| Operating Profit CAGR | +5% | +1% | +10% | — |
| PAT CAGR | -8% | -7% | +2% | — |
| Share Price CAGR | -24% | -10% | -22% | +34% |
| ROE Average | +11% | +12% | +19% | +36% |
| ROCE Average | +13% | +14% | +19% | +26% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.69 | 66.69 | 66.69 | 66.69 | 66.69 | 66.78 | 65.64 | 65.64 | 65.64 | 65.64 |
| FII | 4.28 | 4.27 | 4.07 | 4.01 | 4.12 | 4.01 | 3.7 | 2.14 | 2.27 | 2.05 |
| DII | 3.77 | 3.57 | 3.52 | 3.52 | 3.52 | 4.01 | 4.04 | 4.48 | 4.87 | 4.71 |
| Public | 25.26 | 25.47 | 25.72 | 25.78 | 25.67 | 25.2 | 26.62 | 27.74 | 27.22 | 27.6 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.55 | 4.55 | 4.55 | 4.55 | 4.55 | 4.56 | 4.56 | 4.56 | 4.56 | 4.56 |
| FII | 0.29 | 0.29 | 0.28 | 0.27 | 0.28 | 0.27 | 0.26 | 0.15 | 0.16 | 0.14 |
| DII | 0.26 | 0.24 | 0.24 | 0.24 | 0.24 | 0.27 | 0.28 | 0.31 | 0.34 | 0.33 |
| Public | 1.72 | 1.74 | 1.76 | 1.76 | 1.75 | 1.72 | 1.85 | 1.93 | 1.89 | 1.92 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.95 | 6.95 | 6.95 | 6.95 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.